STAR:NSE
Strides Pharma Science Ltd
₹1,016.00
arrow_downward
-1.51%(-15.60) 1D
Jul 24, 3:30:00 PM GMT+5:30 · INR
search
All symbols
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for STAR...
Open
₹1,031.60
High
₹1,034.40
Low
₹1,014.60
Mkt. cap
93.65B
Avg. vol.
165.06K
Volume
80.52K
Dividend
0.49%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
16.84
52-wk high
₹1,231.00
52-wk low
₹768.65
EPS
₹60.34
Shares outstanding
89.55M
No. of employees
4K
Open
₹1,031.60
High
₹1,034.40
Low
₹1,014.60
Mkt. cap
93.65B
Avg. vol.
165.06K
Volume
80.52K
Dividend
0.49%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
16.84
52-wk high
₹1,231.00
52-wk low
₹768.65
EPS
₹60.34
Shares outstanding
89.55M
No. of employees
4K
News stories
From sources across the web
Simply Wall Street
·
15 minutes ago
USA Rare Earth (USAR) Acquires 13.6% Of Carester To Deepen Its European Footprint
MarketBeat
·
50 minutes ago
Short Interest in M3-Brigade Acquisition V Corp. (NASDAQ:MBAV) Drops By 97.2%
Simply Wall Street
·
15 minutes ago
Streaming Stocks Retail Investors May Revisit After The Paramount Warner Bros Deal Pause
Fox Business
·
13 hours ago
Nasdaq slides: Magnificent Seven wipes out $797 billion in market value
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India.
Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies.
Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3.54K
Founded1990
HeadquartersBengaluru, Karnataka, India
SectorPharmaceutical industry
Websitestrides.com
Next call in 6 days
Fri, Jul 31, 1:30 PM
Fiscal period
Q1 2027
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
- / 13.32B
Fiscal Q1 2027 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in INR | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
Revenue | 11.20B | 12.21B | 11.95B | 13.23B |
Cost of goods sold | 4.44B | 5.15B | 4.63B | 7.19B |
Cost of revenue | 4.44B | 5.15B | 4.63B | 7.19B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.26B | 2.27B | 2.30B | 3.45B |
Operating expense | 5.06B | 5.24B | 5.46B | 4.91B |
Total operating expenses | 9.51B | 10.39B | 10.09B | 12.10B |
Operating income | 1.69B | 1.82B | 1.85B | 1.13B |
Other non operating income | -388.77M | 271.40M | 1.07B | -1.66B |
EBT including unusual items | 1.22B | 1.53B | 2.45B | 1.48B |
EBT excluding unusual items | 1.30B | 1.62B | 2.49B | 502.07M |
Income tax expense | 164.50M | 215.93M | 373.53M | 187.70M |
Effective tax rate | 13.48% | 14.10% | 15.22% | 12.68% |
Other operating expenses | 2.32B | 2.47B | 2.66B | 928.53M |
Net income | 996.08M | 1.28B | 2.02B | 1.27B |
Net profit margin | 8.90% | 10.45% | 16.92% | 9.59% |
Earnings per share | - | - | - | - |
Interest and investment income | - | - | - | 404.82M |
Interest expense | - | -461.27M | -433.79M | -130.82M |
Net interest expenses | - | -461.27M | -433.79M | 274.00M |
Depreciation and amortization charges | 488.86M | 496.43M | 506.23M | 532.49M |
EBITDA | 2.09B | 2.31B | 2.25B | 1.55B |
Gain or loss from assets sale | - | - | - | - |
AI content may include mistakes. Learn more